4[4]Paul A. Body fluid space and blood pressure in hemodialysis patients during amelioration of anemia with erythropoietin. Am J Kid Dis, 1990,16:438 - 442.
5[5]Hvang C, Davis G,Johns EJ. Roles of hematocrit in mediating the actions of chronic erythtropoietic treatment on blood pressure and renal haemodynamic in the rat. Clin Sci, 1993,85:717-724.
6[6]Willo X, Ratleler M, Nobel NA. Cytodines and L - Arginine in renal injury and repair. Am J Physiol, 1994,267:197- 204.
2Muirhead N ,Bargman J,Burgess E,et al. Evidence-based recommendations for the clinical use of recombinant human erythropoietin. Am J Kidney Dis, 1995(supple 1 ):1.
3Hon G,Vaziri ND,Kaupke CJ,et al.Lack of a fast-acting effect of erythropoietin on arterial blood pressure and endothelin level. Artif Organs. 1995,19:188.
2Eschbach JW, Egrie J, Down MR, et al. Correction of the anemia of end stage renal disease with recombinant human erythropioetin,result of a combined phase and clinical trial[J].New Engl J Med, 1987,316(1) : 73-78.
3Vaziri ND. Mechanism of erythropoietin-indueed hypertension[J]. Am J Kidney Dis,1999.33(5) 1821-828.
4Vaziri ND,Tamai O, Kohno K, et al. Cardiovascular effects of erythropoietin and anemia correction [J]. Curr Opin Nephrol Hyoertens,2001, 10(5) :633-637.
5Parker KP,Mitch WE,Stivelman JC,et al. Safety and efficacy of low dose subcutaneous erythropoietin in hemodialysis patients[J]. J Am Soc Nephrol, 1997,8(5) :288-293.
6Lefebvre P, Duh MS, Mody SH, et al. The economic impact of epoetin alfa therapy on delaying time to dialysis in elderly pa- tients with chronic kidney disease. Dis Manag,2007,10 ( 1 ) :37 -45.
